Last reviewed · How we verify

NCT07145489

Infrared Photobiomodulation in Humans With Epilepsy

Recruiting now NA Last updated 4 February 2026
What this trial tests

NA trial testing photobiomodulation in Drug Resistant Epilepsy in 13 participants. Currently enrolling.

Timeline
25 November 2025
Primary endpoint
25 September 2026
25 September 2027

Quick facts

Lead sponsorBeth Israel Deaconess Medical Center
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment13
Start date25 November 2025
Primary completion25 September 2026
Estimated completion25 September 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Beth Israel Deaconess Medical Center

Who can join

18 and older, any sex, with Drug Resistant Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of photobiomodulation

Trials testing the same drug.

Other recruiting trials for Drug Resistant Epilepsy

Currently open trials in the same condition.

Other Beth Israel Deaconess Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07145489.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing